Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1/flk-2), VEGFR-2 (flk-1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. FLT-1 (fms-like tyrosine kinase or VEGF-R1, human 1338 aa, rat 1336 aa, and mouse 1330aa), a putative receptor protein tyrosine kinase, is a receptor for VEGF and PLGF. It is type 1 membrane protein. It is expressed in normal lung, placenta, liver, kidney, heart, and brain but not in tumor. Source: 17aa peptide of human FLT1. Location: ~ C-terminal, Cytoplasmic Applications: ELISA: Use 50-100ng of control peptide/well). Species Sequence Homology: Mouse, rat-83%. No significant sequence homology is seen with human FLK-1 or other related kinases. Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Reinheit:
Purified
Formulierung:
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
